SCHEMBL1639481

SCHEMBL1639481

Cc1ccc(O)c(/C=N\NC(=O)c2ccccc2O)c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 3/20 0.76
KMT2A Q03164 6/20 0.72
KDM4E B2RXH2 5/20 0.72
MEN1 O00255 4/20 0.72
MAPK1 P28482 3/20 0.72
TP53 P04637 1/20 0.72
CYP3A4 P08684 1/20 0.72
CYP2D6 P10635 1/20 0.72
HPGD P15428 1/20 0.72
HSD17B10 Q99714 1/20 0.72
TDP1 Q9NUW8 1/20 0.72
MAPT P10636 5/20 0.66
HTT P42858 4/20 0.66
LMNA P02545 3/20 0.66
BLM P54132 1/20 0.66
NTRK1 P04629 3/20 0.65
PKM P14618 1/20 0.65
KDM1A O60341 1/20 0.61
ALOX12 P18054 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1639483 1.00 PIK3CG (0.76) PIK3CGKMT2AKDM4EMEN1MAPK1
SCHEMBL684664 1.00 PIK3CG (0.76) PIK3CGKMT2AKDM4EMEN1MAPK1
SCHEMBL14949044 0.89 PIK3CG (0.81) PIK3CGKMT2AKDM4EMEN1MAPK1
SCHEMBL685300 0.89 PIK3CG (0.83) PIK3CGKMT2AKDM4EMEN1MAPK1
SCHEMBL13972116 0.88 PIK3CG (0.70) PIK3CGKMT2AKDM4EMEN1MAPK1
SCHEMBL13972156 0.88 PIK3CG (0.63) PIK3CGKMT2AKDM4EMEN1MAPK1
SCHEMBL16271266 0.86 AR (0.76) PIK3CGKMT2AMEN1MAPTGAA
SCHEMBL684666 0.85 PIK3CG (0.60) PIK3CGKMT2AKDM4EMEN1MAPK1
SCHEMBL6569744 0.85 PIK3CG (0.62) PIK3CGKDM4ETP53MAPTHTT
SCHEMBL6569747 0.85 PIK3CG (0.62) PIK3CGKDM4ETP53MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
EP-2194975-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS Acumen Pharmaceuticals, Inc. (US) 2010-06-16 EP disclosed
WO-2009009768-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS ACUMEN PHARMACEUTICALS, INC. (US) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS APP, APBA1, BACE1 PIK3CG 4847/4885KMT2A 3625/4885KDM4E 4638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.